Thursday, April 3, 2025
Unity Biotechnology Reports Positive Results for UBX1325 in DME Trial
Unity Biotechnology reports that treatment with UBX1325 resulted in vision gains comparable to aflibercept at weeks 24 and 36 in a difficult-to-treat patient population.